A lifespan-extending drug has limited effects on aging

July 25, 2013

The immunosuppressive drug rapamycin has been shown to increase longevity in mice even when treatment begins at an advanced age. It is unclear if the extension of life also correlates with prolonged health and vigor.

In the current issue of the Journal of Clinical Investigation, Dan Ehninger and colleagues at the German Center for Neurodegenrative Diseases evaluated age-associated characteristics in mice treated with . They found that rapamycin improved memory and spatial learning, reduced thyroid follicle size, and reduced body fat in older mice. However, many of these same attributes were also improved in young mice treated with the drug, indicating an age-independent drug effect.

The prevalence of cancer, a common cause of mouse mortality, was also decreased in older treated mice. The authors did find that rapamycin treatment had no effect on several age related symptoms, including cardiovascular and liver function, loss of muscle mass, strength retention, or balance.

These data suggest that rapamycin treatment may increase lifespan through reduction of , and the drug may be useful for relief of some age related conditions.

In the accompanying commentary, Arlan Richards of the University of Texas Health Science Center at San Antonio suggests that clinical trials to study the effect of rapamycin on age related neurodegenerative diseases of the elderly such as Alzheimer's disease should be considered.

Explore further: Lifespan-extending drug given late in life reverses age-related heart disease in mice

More information: J Clin Invest. doi:10.1172/JCI67674

Related Stories

Easter Island drug raises cognition throughout life span

June 29, 2012

Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer's disease. Texas scientists seeking a way to prevent this decline reported exciting results this week with ...

Study reveals how cancer drug causes diabetic-like state

April 3, 2012

Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

wealthychef
not rated yet Aug 30, 2013
There must be a mathematical way of testing the hypothesis that "rapamycin treatment may increase lifespan through reduction of cancer rates" based on the study data plus known cancer incidence, no?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.